Home / 2021 / February / 01

Daily Archives: February 1, 2021

Philips expands remote patient management with the introduction of Medical Tablet with advanced software

February 1, 2021

  • New solution available in North America, Europe and Japan provides remote access to patient data to improve workflows to better manage increases in patient volume
  • Offers full remote information access, can be easily deployed and enables a fully portable setup in emergency situations, including COVID-19

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced the Philips Medical Tablet, an end-to-end, easy-to-implement, portable monitoring kit designed to help clinicians remotely monitor larger patient populations during emergency situations, like the COVID-19 pandemic. The Medical Tablet integrates with Philips advanced IntelliVue XDS software to enable remote access of patient monitoring information, allowing clinicians to care for patients outside of the hospital setting. This solution is not tied to a central monitoring station and can therefore be operated through WiFi connection, making it easy to deploy and integrate into existing clinical structures and workflows. Additionally, with the Philips Medical Tablet, clinicians experience less exposure to infected patients, and can increase efficiency through less personal protective equipment (PPE) changing, ultimately improving patient and clinician safety.

The COVID-19 pandemic has created a variety of challenges across multiple care settings within the hospital, including higher than normal patient volume in emergency rooms, personnel shortages, reduced bed capacity and limited resources, particularly PPE. These challenges often lead to overcrowding, increased clinician workload, demand on resources and the added obstacle of trying to create separation between infected and non-infected patients to minimize the spread of disease.

In an effort to alleviate these challenges, hospitals are creating temporary care settings for COVID-19 patients outside of the hospital or in isolation wards, making remote and easily transferable tools essential in delivering consistent and quality care. During a time when both patient and clinician health and safety are paramount, the Philips Medical Tablet using XDS software can connect to multiple IntelliVue monitors in the same network, allowing clinicians to remotely monitor multiple patients to reduce contact as well as lessen bedside monitoring disturbances and interruptions.

“As clinicians work to navigate increased workloads, safety concerns, and transitions to remote care settings, they require solutions that map to these increasingly challenging circumstances,” said Peter Ziese, General Manager of Monitoring Analytics at Philips. “The Philips Medical Tablet with IntelliVue XDS software gives clinicians critical patient data like vital signs and clinical decision support applications right at their fingertips, empowering them to make informed care decisions no matter where they are.”

Outside of emergency-use situations, the Philips Medical Tablet with IntelliVue XDS software can be used as an extended screen, working as a companion to the IntelliVue monitor to display meaningful patient information through clinical decision support tools. It can also act as a clinical workspace, combining patient monitoring views and the hospital’s IT applications, allowing clinicians to simultaneously interact across multiple systems for enhanced patient care.

The Philips Medical Tablet, integrated with the IntelliVue XDS software joins a growing portfolio of solutions aimed at addressing the challenges and changes in patient care brought upon by COVID-19. As both patient safety concerns and clinician workloads rise, Philips’ remote patient monitoring services provide clinicians with the tools they need to help improve patient outcomes. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability. To learn more about the Philips Medical Tablet please visit here.

For further information, please contact:

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
E-mail: anna.hogrebe@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.


Junshi Biosciences and Coherus BioSciences Announce Collaboration to Co-Develop Anti-PD-1 Antibody, Toripalimab, in U.S. and Canada

  • Junshi Biosciences to receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in US and Canada
  • The first toripalimab BLA to be filed with the US FDA for nasopharyngeal carcinoma later this year

SHANGHAI, China, Feb. 01, 2021 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, today announced a collaboration with Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) for the development and commercialization of toripalimab, Junshi Biosciences’ anti-PD-1 antibody, in the United States and Canada.

Under the terms of the agreement, Junshi Biosciences will receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised). Junshi Biosciences and Coherus will co-develop toripalimab, and Coherus will be responsible for all commercial activities in US and Canada. Junshi Biosciences has also granted Coherus options to JS006 (an anti-TIGIT antibody) and JS018-1 (a next generation engineered IL-2 cytokine), as well as first negotiation rights to two early-stage checkpoint inhibitor antibodies.

“We believe Coherus is the ideal partner for us in North America. Their commercial team has demonstrated remarkable ability to gain significant share of the oncology market against entrenched large competitors,” said Dr. Ning LI, CEO of Junshi Biosciences. “Toripalimab could be the first marketed Chinese anti-PD-1 antibody in the overseas market. The collaboration with Coherus will be a critical step to build up our global commercial network. We look forward to working closely with Coherus to establish toripalimab’s position in the United States and Canadian markets in order to provide patients with affordable high-quality innovative care.”

“Toripalimab has a compelling clinical profile with impressive efficacy and safety, and we are thrilled to collaborate with Junshi Biosciences to deliver patient benefit in the United States and Canada,” said Denny Lanfear, CEO of Coherus. “Our mission has always been to increase patient access to important medicines and to deliver significant health care system savings. This transaction builds on that mission to include the rapidly growing checkpoint inhibitor market, which is expected to exceed US$25 billion by 2025, and provides us the essential backbone drug for development of next-generation combination therapies.”

More than 2,100 patients have received toripalimab treatment in clinical trials, and toripalimab is approved for second-line treatment of unresectable or metastatic melanoma in China where it is marketed by Junshi Biosciences and is included on the National Reimbursement Drug List (NRDL). Over the next three years, significant data are expected to read out from the extensive registrational development program, which includes 15 ongoing or completed international/domestic multi-center pivotal clinical trials evaluating toripalimab in multiple treatment settings for a broad range of solid tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

The United States Food and Drug Administration (FDA) has granted a breakthrough therapy designation to toripalimab for nasopharyngeal carcinoma (NPC), and the first toripalimab Biologics License Application (BLA) is expected to be filed with the FDA for this indication later this year. Additionally, FDA has granted Fast Track status for the development of toripalimab for the treatment of mucosal melanoma, and orphan drug designation for NPC, mucosal melanoma and soft tissue sarcoma. Junshi Biosciences and Coherus plan to file additional toripalimab BLAs with the FDA over the next two years for several rare and highly prevalent cancers, including non small cell lung cancer (NSCLC).

As part of the collaboration, Coherus has also acquired options or first negotiation rights to four of Junshi Biosciences’ novel oncology molecules. The Companies may develop toripalimab in combination with one or more of these four compounds, and potentially with other cancer drugs:

  • An option to JS006, an antibody targeting TIGIT, a clinically validated immune inhibitory checkpoint. Anti-TIGIT antibodies have demonstrated significant synergistic anti-tumor activity in combination with anti-PD-1 antibodies. JS006 is expected to enter global clinical development later this year. The option term expires prior to initiation of Phase 2 development.
  • An option to JS018-1, a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T-cells and natural killer (“NK”) cells. The option term expires prior to initiation of Phase 2 development.
  • First negotiation rights to two undisclosed early-stage novel oncology programs directed against immune checkpoint molecules.

Terms of the Junshi Biosciences – Coherus collaboration
Under the terms of the agreement, Junshi Biosciences will receive up to an aggregate of US$1.11 billion of upfront payment, exercise fee and milestone payments from Coherus for the grant of the license of toripalimab and the two option programs (if exercised) in the United States and Canada.

Junshi Biosciences will grant Coherus exclusive rights to toripalimab in the United States and Canada as well as options in these territories to Junshi Biosciences’ JS006 and JS018-1. Coherus will also have first negotiation rights to two undisclosed preclinical immuno-oncology programs. Junshi Biosciences will receive an upfront payment of US$150 million. For toripalimab, Junshi Bioscience will receive 20% royalty on the annual net sales of toripalimab and up to an aggregate $380 million in one-time payments for the achievement of various milestones. For JS006 and JS108-1, Junshi Biosciences will receive an opt-in payment of $35 million per program. Additionally, for each program, Junshi Biosciences will receive 18% royalty on the annual net sales and up to an aggregate $255 million for the achievement of various milestones. The Companies will collaborate on the development of toripalimab and other licensed compounds, and Coherus will pay for a portion of these co-development activities up to a maximum of US$25 million per licensed compound per year.

About toripalimab (TUOYI®)
Toripalimab is the first domestic anti-PD-1 monoclonal antibody to obtain a marketing approval in China. So far, more than thirty company-sponsored clinical studies covering more than fifteen indications have been conducted globally, including in China and the United States. On December 17, 2018, Toripalimab obtained a conditional approval from the NMPA for the second-line treatment of patients with unresectable or metastatic melanoma. Supplemental NDAs of toripalimab for the third-line treatment of recurrent/metastatic nasopharyngeal carcinoma and second-line treatment of metastatic urothelial carcinoma were accepted by the NMPA in April and May 2020, respectively. Both supplemental NDAs received priority review designations from the NMPA in July 2020. In December 2020, toripalimab was included in the National Reimbursement Drug List (NRDL) for the treatment of melanoma by the China National Healthcare Security Administration (NHSA).

In the United States, the FDA has granted toripalimab breakthrough therapy designation for the treatment of recurrent/metastatic nasopharyngeal carcinoma, Fast Track designation for mucosal melanoma, and orphan drug designation for the treatment of nasopharyngeal carcinoma, mucosal melanoma and soft tissue sarcoma.

About the toripalimab clinical development program
Toripalimab is being evaluated in an extensive registrational clinical development program for a broad range of solid tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

  • Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Patients With Locally Advanced or Metastatic Melanoma (POLARIS-01) – NCT03013101
  • Phase 1b/2 trial evaluating toripalimab in patients with advanced gastric adenocarcinoma, ESCC, NPC and head and neck squamous cell carcinoma (POLARIS-02) – NCT02915432
  • Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma (POLARIS-03) – NCT03113266
  • A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers – NCT04603040
  • Phase III Study of Comparing TORIPALIMAB INJECTION Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasophapyngeal Cancer – NCT03581786
  • Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Curative Hepatic Resection (JUPITER-04) – NCT03859128
  • A Phase III Study to Investigate Toripalimab Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma (JS001) – NCT03430297
  • A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC (CHOICE-01) – NCT03856411
  • Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER-06) – NCT03829969
  • Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI – NCT03924050
  • Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment (TORCHLIGHT) – NCT04085276
  • Phase 3 trial comparing toripalimab + lenvantinib vs. lenvantinib alone as a 1st line treatment for patients with advanced HCC – NCT04523493
  • Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer – NCT04012606
  • A Study of Toripalimab or Placebo Plus Chemotherapy as Treatment in Early Stage NSCLC – NCT04158440
  • Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer – NCT04394975
  • A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma – NCT04568304

About JS006
JS006 is a recombinant humanized IgG4κ monoclonal antibody against human TIGIT specifically, developed independently by Junshi Biosciences. According to the results of pre-clinical studies, JS006 can specifically block the TIGIT-PVR pathway.

About JS018-1
JS018-1 is a next-generation engineered IL-2 cytokine designed to inhibit stimulation of regulatory T cells while retaining stimulatory activity on effector T-cells and natural killer (NK) cells.

About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R & D pipeline comprising 27 innovative drug candidates and 2 biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of our continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences, Inc.
Coherus is a commercial stage biopharmaceutical company with the mission to increase patient access to cost-effective medicines that can have a major impact on their lives and to deliver significant savings to the health care system.

In January 2021, Coherus in-licensed Junshi Biosciences’ toripalimab, an anti-PD-1 antibody, which will be a cornerstone of Coherus’ strategy to build a leading immuno-oncology franchise in the United States and Canada funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

For additional information, please visit www.coherus.com.

Contact Information

IR Team:
Junshi Biosciences
+ 86 021-2250 0300

Solebury Trout
Bob Ai
+ 1 646-389-6658

PR Team:
Junshi Biosciences
Zhi Li
+ 86 021-6105 8800

Aberdeen International Diversifies Into Clean Energy Investments With Agreement to Acquire a Significant Interest in AES-100 Inc., the World’s Only Technology Capable of Producing High Purity Green Hydrogen at

AES-100 is the Sole Owner of the Intellectual Property Related to the Advanced Electrolyzer System (AES) Allowing low Cost Hydrogen Production With no Greenhouse gas Emissions

TORONTO, Feb. 01, 2021 (GLOBE NEWSWIRE) — Aberdeen International Inc. (“Aberdeen” or the “Company”) (TSX: AAB) is pleased to announce it has entered into a definitive agreement to acquire 41.67% of AES-100 Inc. AES-100 Inc. has acquired exclusive rights and all intellectual property pertaining to T2M Global’s Advanced Electrolyzer System for the production of hydrogen from dilute syngas (the “Transaction”). T2M Global is the world’s leader in clean energy technology using hydrogen with zero carbon footprint and no greenhouse gas emissions. The technology is revolutionzing the use of fuel cells for transportation and is expected to be a major contributor to the world wide goal of zero carbon footprint by 2050, as recommended by the Paris Accord on Greenhouse Gas emissions.

“Greenhouse gases are the single major cause of pollution and planet global warming. Today the world produces over 27 billion tons of greenhouse gases per year. With the world’s population expected to grow to 10 billion by 2050, reduction of greenhouse gases and producing a clean energy footprint is critical to the survival of mankind”, said Stan Bharti, President and CEO of Aberdeen.

The Advanced Electrolyzer System (AES) is a world-class system created by T2M Global and assigned to AES-100 Inc. Its proprietary technology allows for much lower cost production of hydrogen with no greenhouse gas emissions. AES is the only technology capable of producing high purity green hydrogen at highly competitive costs. AES targets <$5/kg H2, a significant and material improvement from the $10-15/kg H2 levels currently in the marketplace.  This significant cost savings through AES should accelerate the adoption of hydrogen technology andpromote growth of fuel cell vehicle and renewable energy sectors.

Pinakin Patel, co-founder of T2M Global commented, “Currently dilute syngas is mostly wasted or underutilized because it is too expensive to upgrade to higher value hydrogen. AES converts this wasted resource to a profit center. AES is a highly modular technology for deployment in multiple market segments and phase capacity addition.. Preliminary estimates for the worldwide dilute syngas hydrogen market show it is valued at well over $50B/yr. Our world-class AES technology provides a foundation to capture a large portion of this market.”

T2M Global has put together a team of world-renowned experts in the hydrogen industry with over 300 years of relevant experience. This includes technology development, modular design for manufacturing and commercialization in multiple markets. The team’s experience in market responsive product development, cost reduction and service agreements will be available to AES-100 Inc. as it advances the AES technology. Most notably, the team includes:

Pinakin Patel (President) – World leader in hydrogen and fuel cell technologies with over 40 years of experience and 30+ patents. Has received over $500 million in R&D funding for development of projects worldwide. Recipient of prestigious awards from US-DOE, State of Connecticut, ASME, Electrochemical Society and others. Supported dozens of start-ups in alternate energy and associated supply chain development, including strategic alliance and funding development. Highly successful track record with multi-national sponsors, including BASF, Sempra, Exxon, Mitsubishi, Haldor Topsoe, EPRI, NASA, California State agencies, such as CARB and CEC, Canada-SDTC, and many others.

Dr. Ludwig Lipp (Vice President) – Lead project manager with deep expertise in fuel cells and hydrogen, with over 25 years of experience and 10+ patents. Secured over 25 million dollars in R&D funds. Recipient of the 2009 DOE Hydrogen Program R&D Award, in recognition of outstanding contributions to electrochemical hydrogen compression (EHC). Managed over a dozen interdisciplinary R&D projects and holds the world record for electrochemical hydrogen compression with 30,000 hours of operation.

Pursuant to the Transaction, Aberdeen shall invest $1,000,000 per year into AES-100 Inc. for a period of two years following the closing of the Transaction.

Closing of the Transaction to acquire 41.67% of AES-100 Inc. is subject to, among other things, compliance with all applicable regulatory requirements and receipts of all necessary regulatory, corporate, third-party, board and shareholder approvals, including the approval of the Toronto Stock Exchange. There can be no assurances that the Transaction will be completed as proposed, or at all. The Transaction is an arms-length transaction and no change in management or the board of directors of Aberdeen is contemplated.


Aberdeen International is a global resource investment company and merchant bank focused on small capitalization companies in the mining and metals and renewable energy sectors.

For additional information, please visit our website at www.aberdeeninternational.ca.

For further information, please contact:

Ryan Ptolemy
Chief Financial Officer
Aberdeen International Inc.
+1 416-861-5882

This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding: the acquisition by Aberdeen of 41.67% of AES-100 Inc.; the merits and applications of the AES technology; the potential cost savings and cost advantages of the AES technology; the renewable energy sectors, including hydrogen and the Company’s future plans. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking information, including risks inherent in the mining industry and risks described in the public disclosure of the Company which is available under the profile of the Company on SEDAR at www.sedar.com and on the Company’s website at www.aberdeeninternational.com. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

Vitruvian to acquire majority of Expereo

AMSTERDAM, Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) — Vitruvian Partners, the international growth capital and buyout firm, has reached an agreement with Apax Partners sas, the European private equity firm based in Paris, to acquire a majority shareholding in Expereo, the world’s leading provider of Managed Internet, Cloud access and SD-WAN solutions. Apax Partners will remain as a minority shareholder alongside Vitruvian Partners and the company’s management team, who will continue to lead the business. The completion of the transaction is subject to obtaining customary merger control clearances.

Expereo has a strong track record of growth, financial performance and value-enhancing acquisitions, solidifying its position as a market leader in providing managed Global Internet and network connectivity solutions to its communication service provider partners and an impressive array of multinational corporate customers spanning the globe.

“Vitruvian Partners will further bolster our ambitious growth trajectory, enabling us to capitalize even faster on the fundamental changes and opportunities digital transformation brings in the global network and cloud connectivity space,” says Irwin Fouwels, CEO of Expereo. “Vitruvian and the continued support of Apax Partners, will enable us to further build out our leadership position at scale whilst broadening our services suite, enabling our global enterprise customers’ network transformation and cloud-first strategies with enhanced internet and cloud access services with a single, best-in-class, digital customer experience.”

David Nahama, Senior Partner at Vitruvian Partners, adds:
“We have been tracking Expereo since 2016 and have seen the company consistently outperform, and more recently make multiple significant strategic acquisitions. Expereo has established a global leadership position in the highly attractive global cloud and software-defined networking market, allowing it to deliver compelling and differentiated solutions to its customers, underpinning its attractiveness from an investment perspective. We approached Irwin and Thomas late last year and are delighted to be partnering with the Expereo team and Apax on the next significant chapter of Expereo’s expansion and success.” Joe O’Mara, Partner at Vitruvian Partners, concluded: “Together with Apax, we believe we have significant capital and operational capabilities to support Expereo’s growth and acquisition aspirations.”

Thomas de Villeneuve, Partner at Apax Partners, says: “The rapid adoption of cloud-based applications and SD-WAN technologies puts Internet-based WAN solutions at the center of multinational companies’ business models. Expereo has delivered impressive growth since we invested in the business and truly capitalized on these technology trends. We are extremely pleased to continue on this success journey together with Vitruvian, Irwin and his team.”

 About Vitruvian

Vitruvian is an international growth capital and buyout firm headquartered in London with offices across London, Stockholm, Munich, Luxembourg, San Francisco, and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across industries spanning information technology, financial services, life sciences & healthcare, media, and business and consumer services. Vitruvian Funds have backed over 50 companies and have assets under management of approximately €10 billion. Notable investments to date include global market leaders and innovators in their field such as Voxbone, Bitdefender, Farfetch, Just Eat, Trustpilot, Easypark, Unifaun, Marqeta Global–e  and CRF Health, Vitruvian is a signatory of the UN supported Principles of Responsible Investment (“PRI”).


About Expereo

Expereo is the leading provider of managed network solutions, including Global internet connectivity, SD-WAN, and Cloud Acceleration services. Expereo is the trusted partner of 30% of Fortune 500 companies and powers enterprise and government sites worldwide, helping to enhance every business’ productivity with flexible and optimal Internet performance.


About Apax Partners

Expereo was acquired by Apax Partners in 2018.
Apax Partners is a leading European private equity firm based in Paris. With over 45 years of experience, Apax Partners provides long-term equity financing to build and strengthen world-class companies. Funds managed and advised by Apax Partners exceed €4 billion. These funds invest in fast-growing middle-market companies across four sectors of specialisation: Tech & Telecom, Consumer, Healthcare and Services.

Paris-headquartered Apax Partners sas (www.apax.fr) and London-headquartered Apax Partners LLP (www.apax.com) have a shared history but are separate, independent private equity firms.


Vitruvian was advised by Freshfields, Bruckhaus Deringer (legal), Nielen Schuman (corporate finance & debt advisory), Bain & Company (commercial due diligence), FTI Consulting (financial due diligence) and PwC (tax). Apax was advised by Weil, Gotshal & Manges.

© Expereo 2021

Conor McGee

Orbitare selects Spire’s Orbital Service to launch their innovative IP communications service

Two missions of the in-orbit demonstrator of Spaceloop will go to orbit in April and June 2021 onboard Spire satellites

LUXEMBOURG and SAN FRANCISCO, Feb. 01, 2021 (GLOBE NEWSWIRE) — Orbitare, an innovative start-up developing Internet Protocol (IP) communications over their own satellite network, and Spire Global, one of the world’s largest space-powered Earth Information companies, today announced the execution of an agreement to begin deploying Orbitare’s Spaceloop on Spire’s nanosatellite constellation starting with a dual-mission in-orbit validation of its communications protocols.

Spaceloop is Orbitare’s personal satellite communication network in Low Earth Orbit developed and built in Europe and designed to deliver IP messaging, email and file transfer capabilities to any location in the world, at the most affordable price and ease of use. Spaceloop aims at keeping people always safe and connected, and will allow Orbitare to provide services dedicated to both personal safety – be it at sea, in the mountains or wherever the land network may not be accessible – and to fulfil the growing need for connectivity for social and professional reasons. The development of Spaceloop is co-funded by the Government of Luxembourg within the Luxembourg National Space Programme LuxIMPULSE, which aims at providing funding to help companies established in Luxembourg to bring innovative ideas to market. The programme is managed by the Luxembourg Space Agency and implemented by the European Space Agency. The early demonstrator missions will leverage Spire’s advanced Software Defined Radios (SDRs) infrastructure to host Orbitare’s Spaceloop communications protocols as early as April 2021. Following its success, both companies are looking into further expansion of the Spaceloop service across other satellites in the Spire constellation which will facilitate early and fast access to market and further increase the reach of Orbitare’s satellite fleet.

“We are proud to partner with Spire on the development and deployment of Spaceloop. Our teams are enthusiastically working together to get the demonstration mission of Spaceloop rapidly into space”, said Luis Muñoz, founder and Managing Director of Orbitare. “Thanks to Spire’s Orbital Services, the deployment of our commercial services will be significantly accelerated, allowing Orbitare to reach our customers at a much earlier stage. Moreover, running Spaceloop on Spire’s satellites and ground stations gives Orbitare access to a much larger footprint at no additional capital expenditure. This partnership gives us a level of flexibility that is hard to find in the market.”

In April 2021, Spire will host Spaceloop’s communication software on a software-defined radio (SDRs) on board one of the in-orbit Low Earth Multi-Use Receiver (LEMUR) 3U satellites in a unique approach to space that will allow Orbitare the early start of live communication tests.
By June 2021, Spire will fly Orbitare’s first full-duplex Spaceloop communications payload, developed also in cooperation with Orbitare, to showcase additional comms capabilities. The demonstration program will use Orbitare’s reference end-user terminals and a gateway located in Luxembourg. Spire will manage all satellite operations through its Missions Operation System and Orbitare will access the payload through an easy-to-use customer API.

With this partnership Spire commercializes a new Space as a Service subscription model allowing Orbitare to implement its mission at competitive price and without heavy upfront capital expenditure. Spire’s Orbital Services monthly payment plan benefits their customers by reducing high upfront expenditures, enabling predictable service charges distribution, and allows an easier extension of the service provision beyond the lifecycle of the hardware.

“We are extremely proud to host Orbitare’s Spaceloop service and use our Orbital Services to provide them the resources they need in space, on the ground and in the cloud. With our technical and operational expertise paired with a simplified service model we assure Orbitare the fastest, easiest, and most reliable access to Space and roadmap for growth,” said Theresa Condor, GM Orbital Services, Spire Global.

This commercial agreement between Orbitare and Spire demonstrates broad collaboration and innovation capabilities offered within the growing New Space community in Luxembourg, of which both companies are part.

About Spire Global Inc.
Spire is a space-powered data and analytics platform that offers unique datasets and powerful insights about Earth from the ultimate vantage point so organizations can make decisions with confidence, accuracy, and speed. Spire uses the largest multi-purpose satellite constellation to source and enrich data with the most accurate predictive solutions so organizations can rapidly course-correct, deploy resources, mitigate risk, and save lives. Spire gives commercial and government organizations an unprecedented competitive advantage to innovate and solve the world’s toughest problems from space. Spire has offices in San Francisco, Boulder, Washington DC, Glasgow, Luxembourg, Singapore. To learn more, visit spire.com

About Orbitare

Orbitare was founded in 2017 on the observation that 60 years after Sputnik only a mere few thousand satellites are in operation, leaving the vast potential of space largely underutilized and its applications quite away from the common people. With sites in Luxembourg and Switzerland, Orbitare works on finding and developing applications of Space with large and positive impact on society, as their contribution to a better World.

Spaceloop is the first of such applications, taking satellite personal communications to the next level of usability, affordability, and reliability, deservedly making them accessible to all of us. With Spaceloop you will always be safe and connected to those who matter to you, wherever the journey takes you. Natively integrated with the internet, the Spaceloop network is ready for the future. To learn more, visit orbitare.space


Spire: press@spire.com

Orbitare: Luis Muñoz, Director, luis.munoz@orbitare.space

WHO Visits Center In Charge of Early COVID Outbreak

A team of World Health Organization scientists investigating the source of the coronavirus, that first emerged in China’s Hubei province in late 2019, visited a provincial disease control center Monday that was key in the early management of the COVID outbreak.

China did not release any details about the team’s visit to the Hubei Provincial Center for Disease Control. Team member Peter Daszak, however, told reporters it had been a “really good meeting, really important.”

Since the WHO team’s arrival last month, the scientists have also visited the Huanan Seafood Market that was linked to a cluster of COVID-19 cases and at least one of the hospitals in Wuhan that treated some of the first patients. COVID-19 is the disease caused by the coronavirus.

The scientists want to know where the virus originated, in what animal and how it made its way into humans — something that could take years to figure out.

“We continue to ask the questions, we continue to push for more data. … It’s a detective story,” Mike Ryan, top emergency WHO official, told a Geneva news conference Monday.

Maria Van Kerkhove, an American epidemiologist and technical lead on COVID-19 at WHO, said at the news conference that the team is focusing on “the early cases” and “are having very good discussions around that” with their Chinese counterparts.

The outbreak in China led to the worldwide COVID-19 pandemic. The Johns Hopkins Coronavirus Resource Center said Monday there are more than 103 million global COVID-19 infections and more than 2.2 million people have died.

Drop in cases

Cases have fallen worldwide for three consecutive weeks. WHO Director-General Tedros Adhanom Ghebreyesus called the decline “encouraging news” but warned, “We have been here before.”

Speaking Monday at the news conference, Tedros said, “Over the past year, there have been moments in almost all countries when cases declined and governments opened up too quickly, and individuals let down their guard, only for the virus to come roaring back.”

COVID variant

In Britain, health officials said Monday that 11 people in different regions of England have tested positive for the coronavirus variant first identified in South Africa without any links to people who have traveled.

Health Minister Matt Hancock said those in affected areas need to be tested to break the chain of transmission.

“There’s currently no evidence to suggest this variant is any more severe,” he said. “But we need to come down on it hard, and we will.”

Britain is battling a wave of the virus first identified in the southeast of England. The country’s official death toll passed 100,000 last week.

Officials in Madrid, Spain, say they will begin to relax the city’s COVID-19 restrictions later this week, even as other parts of Spain are toughening up measures to stop rising infections. Beginning Friday, a 10 p.m. curfew will be extended to midnight, and gatherings of up to six people will be allowed outdoors.

U.S. relief aid

In the United States, U.S. President Joe Biden is meeting with a group of 10 Republican senators who have proposed $618 billion in coronavirus aid, about a third of the price tag of the $1.9 trillion relief bill that he is calling for.

The United States continues to have more cases than anyplace else at more than 26.2 million. India follows with 10.7 million infections, and Brazil comes in third with 9.2 million cases, according to Johns Hopkins.

New cases of COVID-19 in the United States fell for a third week in a row, though more than a million people are still being infected every week, according to a Reuters analysis of state and county reports and Johns Hopkins. Reuters said it is the first time the United States has seen such an extended decline in cases since last September.

A leading U.S. epidemiologist said Sunday he believes the highly contagious and more deadly British strain of the COVID-19 virus could become the dominant strain in the U.S. in the coming weeks, resulting in a surge of infections “like we have not yet seen in this country.”

Speaking on NBC’s “Meet the Press” Sunday morning news program, Michael Osterholm, who served on Biden’s transition coronavirus advisory board, urged the Biden administration and U.S. municipalities to be diligent in inoculating Americans with the COVID-19 vaccines ahead of the “hurricane” of the British variant.

Vaccination efforts

The European Union announced Sunday that British company AstraZeneca agreed to send 9 million more doses of the vaccine to EU countries.

AstraZeneca will also deliver the doses a week earlier than planned, EU Commission President Ursula von der Leyen said on Twitter, calling the news a “step forward on vaccines.”

On the African continent, only a handful of countries have been able to begin vaccinating their populations.

South Africa’s first coronavirus vaccine doses arrived Monday. President Cyril Ramaphosa and other top officials were at the O.R. Tambo International Airport to receive the 1 million shots of the AstraZeneca vaccine.

On Sunday, Ghana announced it planned to acquire 17.6 million doses by summer, with the first batches arriving by March. It did not say which vaccine the country is getting.

“Our aim is to vaccinate the entire population, with an initial target of 20 million people,” President Nana Akufo-Addo said Sunday.

He also announced stricter measures against the virus, including banning large gatherings, as the country battles a second wave.

Source: Voice of America

Republicans Hold ‘Useful’ Meeting with Biden, But No Deal on COVID Relief

The White House and a group of U.S. Senate Republicans held what the two sides respectively called “substantive and productive” and “frank and very useful” talks Monday about a new round of coronavirus economic relief.

Senator Susan Collins, a Republican from Maine, told reporters following the two-hour meeting with President Joe Biden and Vice President Kamala Harris, “was a very good exchange of views.” She said the two sides did not reach an agreement on a bipartisan package, but that discussions would continue.

“All of us are concerned about struggling families, teetering small businesses and overwhelmed health care system, getting vaccines out and into people’s arms and strengthening our economy and addressing the public health crisis that we face,” Collins said.

Biden has proposed a $1.9 trillion plan, while the Republicans argue the relief should be more targeted with a price tag closer to $600 billion.

A White House statement late Monday said those involved in the negotiations “shared a desire to get help to the American people.” But it said Biden “will not settle for a package that fails to meet the moment.”

Biden has expressed a preference for getting bipartisan support for coronavirus aid, but reiterated Monday that pursuing a path with only the supports of the majority Democrats in Congress is an option.

House and Senate leaders said Monday they would move ahead to approve Biden’s package with a process that does not depend on Republican support for passage.

“The cost of inaction is high and growing, and the time for decisive action is now,” said Senate Majority Leader Chuck Schumer and House Speaker Nancy Pelosi in a statement.

Schumer told lawmakers on the Senate floor Monday, “The risk of doing too little is far greater than the risk of doing too much.”

On Sunday, Schumer complained that the Republicans are not starting near Biden’s spending proposal.

“We cannot do the mistake of 2009 (during the Great Recession) where they whittled down the program so that the amount of relief was so small that the recession lasted four or five years,” Schumer told the New York Daily News.

Both Biden and the Republicans are calling for $160 billion for testing, vaccines and personal protective equipment on top of hundreds of billions that were approved last year as the virus swept into the United States.

But the president and the lawmakers diverge on other aid proposals. Biden wants to increase $300 weekly unemployment insurance payments from the federal government to $400 and extend them through September, while the Republicans want to keep the payments at the current $300 and only through July.

Biden has proposed sending most Americans, all but the biggest wage earners, $1,400 checks on top of the $600 checks that were approved by former President Donald Trump in late December. The Republicans are supporting $1,000 checks for lower-income Americans.

Source: Voice of America